1 citations
,
May 2019 in “The Journal of Sexual Medicine” This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.
11 citations
,
July 2019 in “The Journal of Sexual Medicine” This study suggests that spironolactone may cause hormonally associated vestibulodynia and female sexual arousal disorder, with symptoms improving after discontinuation and use of a topical estrogen/testosterone gel.
237 citations
,
January 2010 in “The Journal of Sexual Medicine” The authors updated recommendations on diagnosing and treating women's sexual dysfunctions, emphasizing a comprehensive assessment approach, while noting the need for further multidisciplinary research.
May 2019 in “The Journal of Sexual Medicine” This study found no baseline factors that predicted flibanserin efficacy for HSDD, though low testosterone or use of hormonal contraceptives were associated with reduced efficacy.
10 citations
,
January 2014 in “Journal of Mid-life Health” This article reviews dermatological problems associated with estrogen deficiency in menopausal women and highlights the importance of dermatologist and gynecologist collaboration, but reports no new clinical results.